Biotech Valuation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation

CRSP 50.19

+1.8%

Nov 21 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: DewDiligence_on_SI who wrote (16925)	5/24/2005 1:23:17 PM
From: tuck	Read Replies (1) of 52153

>>There may still be an opening for one or more of those therapies they can dose less frequently or avoid Lucentis’s non-trivial safety problems.<< Agreed, it's just that the efficacy bar got higher. ALNY, RNAI, indeed holding steady today. Speaking of antisense companies in this context . . . very interesting timing on this Pfizer/Isis ophthalmology deal: Message 21353915 Cheers, Tuck

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next